Clinical Trial Update: Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer [Phase 2]

View source ↗

Summary

A Phase II study evaluating axitinib in patients with unresectable, recurrent, or metastatic head and neck squamous cell carcinoma has been completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Axitinib (Axitinib)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2015-12-09